These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

763 related articles for article (PubMed ID: 22665688)

  • 21. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Impact of Cholinesterase Inhibitors with or without Memantine on Antipsychotic Prescribing.
    Blaszczyk AT; Mang BH; Garza H; Mathys M
    Consult Pharm; 2018 May; 33(5):273-282. PubMed ID: 29789049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of Alzheimer's disease and future approaches].
    Forette F; Hauw JJ
    Therapie; 2010; 65(5):429-37. PubMed ID: 21144478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mémantine (Ebixa): a new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer's disease].
    Gallarda T; Lôo H
    Encephale; 2004; 30(1):69-79. PubMed ID: 15029079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Questions & answers. We've been told that my wife has multi-infarct dementia and that the new drug memantine may help. How is her condition different from Alzheimer's disease, and what could memantine do for her?
    Miller MC
    Harv Ment Health Lett; 2004 Mar; 20(9):8. PubMed ID: 15044129
    [No Abstract]   [Full Text] [Related]  

  • 26. Symptomatic treatments in Alzheimer's disease in 2016: a study from Memory centers in France.
    Hommet C; Novella JL; Auriacombe S; Vercelletto M; Berrut G; Belliard S; Desmidt T; Ceccaldi M
    Geriatr Psychol Neuropsychiatr Vieil; 2016 Sep; 14(3):274-86. PubMed ID: 27651009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
    Feldman HH; Schmitt FA; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
    Prasher VP
    Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drugs for cognitive loss and dementia.
    Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
    Dantoine T; Auriacombe S; Sarazin M; Becker H; Pere JJ; Bourdeix I
    Int J Clin Pract; 2006 Jan; 60(1):110-8. PubMed ID: 16409439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
    Sevilla C; Jiménez Caballero PE; Alfonso V; González-Adalid M
    Dement Geriatr Cogn Disord; 2009; 28(3):196-205. PubMed ID: 19738386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area.
    Araki T; Wake R; Miyaoka T; Kawakami K; Nagahama M; Furuya M; Limoa E; Liaury K; Hashioka S; Murotani K; Horiguchi J
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):881-9. PubMed ID: 24436135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
    Gauthier S; Molinuevo JL
    Alzheimers Dement; 2013 May; 9(3):326-31. PubMed ID: 23110864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
    Modrego PJ; Fayed N; Errea JM; Rios C; Pina MA; Sarasa M
    Eur J Neurol; 2010 Mar; 17(3):405-12. PubMed ID: 19874395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alzheimer's disease: a review of recent developments.
    Salawu FK; Umar JT; Olokoba AB
    Ann Afr Med; 2011; 10(2):73-9. PubMed ID: 21691010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.
    Kerchner GA; Tartaglia MC; Boxer A
    Expert Rev Neurother; 2011 May; 11(5):709-17. PubMed ID: 21728274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.